Sun Pharma’s deal to buy Merck-spinoff Organon ticks the right box on acquisition cost if not R&D

Subscribe to enjoy similar stories.Sun Pharma would appear to have got itself a sweet deal when it agreed to acquire all outstanding shares of US-based Organon for $3.7 billion in cash at $14 per share.The US pharma company had outstanding debt of $8.6 billion at the end of 2025, annual sales of $6.2 billion and adjusted Ebitda of $1.9 billion (i.e., earnings before interest, taxes, depreciation and amortization). Its enterprise value of $11.75 billion, as widely reported, is the sum of its stock value and debt, less cash on hand.

While its price-earnings ratio (a more common yardstick) goes by net income and not Ebidta, the latter calculated per share makes it clear that Sun is paying a competitive price for this maker of assorted healthcare products focused on women’s health and some biosimilars.The company has marketing channels in 140 countries that Sun gets to snap up, apart from production centres in the UK, Netherlands, Belgium, Indonesia, Brazil and Mexico. It does not have a plant in the US, a condition for relief from a 100% US import tariff on patented drugs.But its American lineage is blue chip, as it was spun off from Merck in 2021.

Sun already has some manufacturing capacity in the US and could expand that to qualify for duty exemptions, helped along perhaps by Organon’s antecedents. While this acquisition makes sound commercial sense and catapults Sun into the global league of pharma players, a slight let-down is that it does not give Sun much R&D muscle.

The reason Merck spun Organon out of itself was that it wanted to focus on finding new therapies and vaccines. Sun is buying a subsidiary for legacy drugs that was cleaved apart and listed separately.